CS
VRNA

Candriam SCA’s Verona Pharma VRNA Stock Holding History

Candriam SCA’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-216,400
Closed -$20.5M – 698
2025
Q2 		$20.5M Sell
216,400
-81,355
-27% -$6.02M 0.12% 162
2025
Q1 		$18.9M Sell
297,755
-142,558
-32% -$8.53M 0.12% 166
2024
Q4 		$20.4M Sell
440,313
-332,684
-43% -$12.5M 0.12% 163
2024
Q3 		$22.2M Hold
772,997
– – 0.13% 167
2024
Q2 		$11.2M Buy
+772,997
New +$11.3M 0.07% 241

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Candriam SCA's VRNA Position: Q3 2025 in Review

Candriam SCA sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 216,400 shares — an estimated $20.5M sold.

Candriam SCA first reported a position in VRNA in Q2 2024 and held it in 5 quarters. The position peaked at $22.2M in Q3 2024. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Candriam SCA reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Candriam SCA sold 216,400 Verona Pharma shares in Q3 2025, an estimated $20.5M.
  • Candriam SCA first reported a position in Verona Pharma in Q2 2024 and held it in 5 quarters.
  • Candriam SCA's Verona Pharma position peaked at $22.2M in Q3 2024.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Candriam SCA's 13F filing for Q3 2025, filed 6 Nov 2025.